Immunity to growth factor receptor-bound protein 10, a signal transduction molecule, inhibits the growth of breast cancer in mice

Cancer Research

Volumn 68, Issue 7, 2008, Pages 2463-2470

  O Sullivan, InSug ^a   Chopra, Amla ^a   Carr, Janai ^a   Tae, Sung Kim ^b   Cohen, Edward P ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Korea University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GROWTH FACTOR RECEPTOR BOUND PROTEIN 10; INTERLEUKIN 2; TYROSINE KINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER SURVIVAL; CELL BASED GENE THERAPY; CELL DIVISION; CELL POPULATION; CONTROLLED STUDY; CYTOTOXICITY; DNA LIBRARY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ANIMALS; CANCER VACCINES; CELL GROWTH PROCESSES; DNA, COMPLEMENTARY; FEMALE; FIBROBLASTS; GRB10 ADAPTOR PROTEIN; H-2 ANTIGENS; INTERLEUKIN-2; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C3H; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TRANSDUCTION, GENETIC;

EID: 42049090783     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5685     Document Type: Article

References (47)

1. American Cancer Society. Cancer facts and figures 2005. Atlanta (GA): American Cancer Society; 2005.
2. Bankhead C. Preliminary breast cancer vaccine study shows promise. J Natl Cancer Inst 2007;99:836.
3. Yang E, Hu XF, Xing PX. Advances of MUC1 as a target for breast cancer immunotherapy. Histol Histopathol 2007;8:905-22.
4. Czerniecki BJ, Roses RE, Koski GK. Development of vaccines for high-risk ductal carcinoma in situ of the breast. Cancer Res 2007;67:6531-4.
5. Renard V, Leach DR. Perspectives on the development of a therapeutic HER-2 cancer vaccine. Vaccine 2007;25 Suppl 2:B17-23.
6. Fulton A, Miller F, Weise A, Wei WZ. Prospects of controlling breast cancer metastasis by immune intervention. Breast Dis 2006-2007;26:115-27.
7. Yoshitake Y, Nakatsura T, Monji M. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res 2004;10:6437-48.
8. Russo G, Zegar C, Giordano A. Advantages and limitations of microarray technology in human cancer. Oncogene 2003;22:6497-507.
9. Quraishi I, Rishi M, Feldman M, Wargovich MJ, Weber B. Clinical validation of breast cancer biomarkers using tissue microarray technology. Appl Immunohistochem Mol Morphol 2007;15:45-9.
10. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8:R157.
11. Mu LJ, Kyte JA, Kvalheim G, et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005;93:749-56.
12. + T cell responses in patients with metastatic prostate cancer. J Immunol 2005;174:3798-807.
13. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005;28:496-504.
14. Hus I, Rolinski J, Tabarkiewicz J, et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 2005;19:1621-7.
15. Hayashi T, Nakao K, Nagayama Y, et al. Vaccination with dendritic cells pulsed with apoptotic cells elicits effective antitumor immunity in murine hepatoma models. Int J Oncol 2005;26:1313-9.
16. Cuadros C, Dominguez AL, Lollini PL, et al. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice. Int J Cancer 2005;116:934-43.
17. Dalgleish AG, Whelan MA. Cancer vaccines as a therapeutic modality: the long trek. Cancer Immunol Immunother 2006;55:1025-32.
18. Boon T, Cerrottini JC, Van den Eynde B, van er Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
19. Xu Y, Sette A, Sidney J, Gendler SJ, Franco A. Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention. Immunol Cell Biol 2005;83:440-8.
20. Mukherjee P, Tinder TL, Basu GD, Pathangey LB, Chen L, Gendler SJ. Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 costimulation in a spontaneous breast cancer model. Breast Dis 2004;20:53-63.
21. Allen SD, Garrett JT, Rawale SV, et al. Peptide vaccines of the HER-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo. J Immunol 2007;179:472-82.
22. Svane IM, Pedersen AE, Johansen JS, et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007;56:1485-99.
23. Svane IM, Pedersen AE, Johnsen HE, et al. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004;53:633-41.
24. Seil I, Frei C, Sültmann H, et al. The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer. Int J Cancer 2007;120:2635-42.
25. + cytotoxic T-cell clones specific for NY-BR-1. Cancer Res 2006;66:6826-33.
26. Varga Z, Theurillat JP, Filonenko V, et al. Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. Clin Cancer Res 2006;12:2745-51.
27. Li Y, Lin AW, Zhang X, Wang Y, Wang X, Goodrich DW. Cancer cells and normal cells differ in their requirements for Thoc1. Cancer Res 2007;67:6657-64.
28. Bavoux C, Leopoldino AM, Bergoglio V, et al. Upregulation of the error-prone DNA polymerase κ promotes pleiotropic genetic alterations and tumorigenesis. Cancer Res 2005;65:325-30.
29. Vincent-Salomon A, Ganem-Elbaz C, Manie E, et al. X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors. Cancer Res 2007;67:5134-40.
30. Chopra A, Kim TS, O-Sullivan I, Martinez D, Cohen EP. Treatment of squamous carcinoma in mice with a vaccine enriched for cells that induce immunity to squamous carcinoma - a new vaccination strategy. Int J Cancer 2006;119:339-48.
31. Kim TS, Cohen EP. Immunity to breast cancer in mice immunized with fibroblasts transfected with a cDNA expression library derived from small numbers of breast cancer cells. Cancer Gene Ther 2005;12:890-9.
32. Xue SA, Stauss HJ. Enhancing immune responses for cancer therapy. Cell Mol Immunol 2007;4:173-84.
33. Walewska R, Teobald I, Dunnion D, et al. Preclinical development of hybrid cell vaccines for multiple myeloma. Eur J Haematol 2007;78:11-20.
34. de Zoeten BF, Carr-Brendel V, Cohen EP. Resistance to melanoma in mice immunized with semi-allogeneic fibroblasts transfected with genomic DNA from melanoma cells. J Immunol 1998;160:2915-22.
35. de Zoeten B, Carr-Brendel V, Markovic D, Taylor-Papadimitriou J, Cohen EP. Immunity to breast cancer in mice immunized with semi-allogeneic fibroblasts transfected with DNA from breast cancer cells. J Immunol 1999;162:6934-41.
36. O-Sullivan I, Chopra A, Kim TS, et al. New strategy for the identification of squamous carcinoma antigens that induce therapeutic immune responses in tumor-bearing mice. Cancer Gene Ther 2007;14:389-98.
37. Wigler M, Pellicer A, Silverstein S, Axel R, Urlaub G, Chasin L. DNA-mediated transfer of the adenine phosphoribosyl transferase locus into mammalian cells. Proc Natl Acad Sci U S A 1979;76:1373-6.
38. Hsu C, Kavathas P, Herzenberg LA. Cell-surface antigens expressed on L-cells transfected with whole DNA from non-expressing and expressing cells. Nature 1984;312:68-9.
39. Shih C, Shilo B-Z, Goldfarb MP, Dannenberg A, Weinberg RA. Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci U S A 1979;76:5714-8.
40. Shih C, Weinberg RA. Isolation of a transforming sequence from a human bladder carcinoma cell line. Cell 1982;29:161-9.
41. Smith FM, Holt LJ, Garfield AS, et al. Mice with a disruption of the imprinted Grb10 gene exhibit altered body composition, glucose homeostasis, and insulin signaling during postnatal life. Mol Cell Biol 2007;27:5871-86.
42. Kebache S, Ash J, Annis MG, et al. Grb10 and active Raf-1 kinase promote bad-dependent cell survival. J Biol Chem 2007;282:21873-83.
43. Tezuka N, Brown AM, Yanagawa S. GRB10 binds to LRP6, the Wnt co-receptor and inhibits canonical Wnt signaling pathway. Biochem Biophys Res Commun 2007;356:648-54.
44. Yamasaki-Ishizaki Y, Kayashima T, Mapendano CK, et al. Role of DNA methylation and histone H3 lysine 27 methylation in tissue-specific imprinting of mouse Grb10. Mol Cell Biol 2007;27:732-42.
45. Dufresne AM, Smith RJ. The adapter protein GRB10 is an endogenous negative regulator of insulin-like growth factor signaling. Endocrinology 2005;146:4399-409.
46. Pero SC, Shukla GS, Cookson MM, Flemer S, Jr., Krag DN. Combination treatment with Grb7 peptide and doxorubicin or trastuzumab (Herceptin) results in cooperative cell growth inhibition in breast cancer cells. Br J Cancer 2007;96:1520-5.
47. Guan H, Smirnov DA, Ricciardi RP. Identification of genes associated with adenovirus 12 tumorigenesis by microarray. Virology 2003;25:114-24.